STERIS plc provided revenue guidance for fiscal 2023. For fiscal 2023, constant currency organic revenue growth is now anticipated to be approximately 10%, compared with prior expectations of 11%, reflecting ongoing supply chain challenges and procedure volumes somewhat lighter than anticipated. As reported revenue is expected to increase approximately 9%, reflecting the net impact of acquisitions and divestitures as well as approximately $100 million in anticipated negative impact of foreign currency fluctuations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
229.2 USD | +1.04% | -1.51% | +4.24% |
20/05 | Steris Insider Sold Shares Worth $267,313, According to a Recent SEC Filing | MT |
17/05 | Steris Insider Sold Shares Worth $7,532,366, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.24% | 22.65B | |
-5.56% | 181B | |
-0.11% | 108B | |
-6.17% | 66.12B | |
+2.64% | 50.65B | |
+6.58% | 43.66B | |
+4.91% | 41.3B | |
+21.98% | 31.6B | |
+14.45% | 25.03B | |
-5.81% | 24.16B |
- Stock Market
- Equities
- STE Stock
- News STERIS plc
- STERIS plc Provides Revenue Guidance for Fiscal 2023